Animal study demonstrates reduced hyperglycemia, inflammation, and advanced glycation end-products in diabetic rats treated with algal phycocyanin nanoparticles, suggesting potent therapeutic...
Aim: This study evaluated the effect of Phyocyanin extracted from Chlorophyta Ulva lactuca algae loaded on albumin nano-particles (ULANP) on diabetic rats. Materials and Methods: Fifty albino rats were divided into 5 goups. GPI: control and GPII: rats were injected with alloxan (75 mg /kg) i.p for six consecutive days for induction of diabetes. This group was subdivided into 4 subgroups: GP IIa: (Untreated diabetic): GP IIb: rats were given with ULANP (100 mg/kg).GP IIc: Rats were given ULANP (200 mg/kg) i.p. GP IId: Rats were given insulin (100 unit/ day). Serum NO, interleukin-6 glucose, AGEs and fatty acids profile was determined. Results: Analysis of ULANP by FTIR showed the characteristic band (2100 cm-1~ 3700 cm-1) that is indicated mainly from -COO, – CO and conjugated double bond. These bonds showed spectral bands peak 2985 cm-1 and 2860 cm-1, 2986 cm-1. Administration of ULANP in diabetic rats exerted an anti-inflammatory by lowering NO and IL-6 levels and hypoglycemic effects by decreased glucose and reduced AGEs levels. In addition, ULAPN lowered percent of saturated fatty acids while elevated unsaturated fatty acids percent. Conclusion: It was concluded that, ULAPN is a promising effective anti-inflammatory and hypoglycemic agent compared with other therapeutic agents with lower site effects.
No takes yet. Share an insight, caveat, or question.
Al‐Malki et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: